---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049802"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:36:56.393524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD

## Summary
- EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.
- Study enrolls 25 patients across multiple US centers; 28-week treatment with monthly IV doses of efzofitimod (270 mg or 450 mg) or placebo.
- Primary objective: evaluate efficacy of efzofitimod on pulmonary, cutaneous, and systemic manifestations in SSc-ILD.

## SEC filing metadata
- accession: 0000950170-23-049802
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/0000950170-23-049802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/life-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049802
- JSON: https://secwatch.observer/filing/0000950170-23-049802.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.